$BIOA News

Roth Capital Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $36

BTIG Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $40

BioAge Labs, Inc. (BIOA) Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease Transcript

Bioage Labs Q1 EPS $(0.52) Beats $(0.64) Estimate, Sales $2.772M Beat $1.083M Estimate

BioAge Labs, Inc. (BIOA) Discusses Phase I Results and Development Plans for BGE-102 NLRP3 Inhibitor Transcript

BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans

BioAge Reports Positive Phase 1 Data For BGE-102 Showing Up To 86% hsCRP Reduction With Favorable Safety, Plans Phase 2 Cardiovascular Trial In 2026

BioAge Labs: Oral NLRP3 Inhibitor Could Establish PoC In CV This Year

Needham Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $50

BioAge Labs Files Shelf Prospectus For Offering Of Securities; No Terms Disclosed

Bioage Labs shares are trading lower. The company reported Q4 financial results.

Bioage Labs Q4 EPS $(0.72) Beats $(0.73) Estimate, Sales $3.078M Beat $1.915M Estimate

Bioage Labs shares are trading higher after Citigroup maintained the stock with a Buy rating and raised its price target from $15 to $52.

Citigroup Maintains Buy on Bioage Labs, Raises Price Target to $52

Oppenheimer Initiates Coverage On Bioage Labs with Outperform Rating, Announces Price Target of $60

BioAge Labs shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $9 to $62.

Jefferies Upgrades Bioage Labs to Buy, Raises Price Target to $62

BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China

Piper Sandler Initiates Coverage On Bioage Labs with Overweight Rating, Announces Price Target of $73

BioAge Announces Pricing of Upsized $115.0 Million Public Offering